Neoadjuvant (presurgical) therapy for renal cell carcinoma: A new treatment paradigm for locally advanced and metastatic disease

Christopher G. Wood, Vitaly Margulis

Research output: Contribution to journalArticle

54 Citations (Scopus)

Abstract

BACKGROUND: Although upfront cytoreductive nephrectomy followed by systemic therapy remains the standard of care for metastatic renal cell carcinoma, the addition of novel targeted therapy has prompted a reevaluation of this treatment paradigm. The authors reviewed their experience with neoadjuvant systemic therapy administered before cytoreductive surgery for metastatic, locally recurrent, or regionally advanced renal cell carcinoma. METHODS: The authors compared patients treated with presurgical targeted therapy (with sunitinib, sorafenib, or bevacizumab) with a contemporary group that underwent upfront cytoreductive surgery. RESULTS: The authors found no difference in any perioperative surgical parameters indicative of morbidity or mortality between the 2 groups. Laboratory models of renal cell carcinoma treated with systemic targeted therapy demonstrate specific protein expression profiles that correlate with response to therapy and the development of therapy resistance. CONCLUSIONS: Neoadjuvant (presurgical) targeted therapy before cytoreductive surgery appears safe in the setting of metastatic renal cell carcinoma. It identifies patients who respond to systemic therapy before surgery, thus avoiding highly morbid surgery in patients destined for a poor outcome. Further studies are needed to identify the molecular endpoints associated with treatment response and the development of the resistant phenotype, which will in turn identify novel transduction pathways worthy of therapeutic development.

Original languageEnglish (US)
Pages (from-to)2355-2360
Number of pages6
JournalCancer
Volume115
Issue numberSUPPL. 10
DOIs
StatePublished - May 15 2009

Fingerprint

Neoadjuvant Therapy
Renal Cell Carcinoma
Therapeutics
Standard of Care
Nephrectomy
Morbidity
Phenotype

Keywords

  • Neoadjuvant therapy
  • Nephrectomy
  • Renal cell carcinoma
  • Targeted therapy
  • Transduction pathways

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Neoadjuvant (presurgical) therapy for renal cell carcinoma : A new treatment paradigm for locally advanced and metastatic disease. / Wood, Christopher G.; Margulis, Vitaly.

In: Cancer, Vol. 115, No. SUPPL. 10, 15.05.2009, p. 2355-2360.

Research output: Contribution to journalArticle

@article{f00ccab7f1564780baedc198ae913935,
title = "Neoadjuvant (presurgical) therapy for renal cell carcinoma: A new treatment paradigm for locally advanced and metastatic disease",
abstract = "BACKGROUND: Although upfront cytoreductive nephrectomy followed by systemic therapy remains the standard of care for metastatic renal cell carcinoma, the addition of novel targeted therapy has prompted a reevaluation of this treatment paradigm. The authors reviewed their experience with neoadjuvant systemic therapy administered before cytoreductive surgery for metastatic, locally recurrent, or regionally advanced renal cell carcinoma. METHODS: The authors compared patients treated with presurgical targeted therapy (with sunitinib, sorafenib, or bevacizumab) with a contemporary group that underwent upfront cytoreductive surgery. RESULTS: The authors found no difference in any perioperative surgical parameters indicative of morbidity or mortality between the 2 groups. Laboratory models of renal cell carcinoma treated with systemic targeted therapy demonstrate specific protein expression profiles that correlate with response to therapy and the development of therapy resistance. CONCLUSIONS: Neoadjuvant (presurgical) targeted therapy before cytoreductive surgery appears safe in the setting of metastatic renal cell carcinoma. It identifies patients who respond to systemic therapy before surgery, thus avoiding highly morbid surgery in patients destined for a poor outcome. Further studies are needed to identify the molecular endpoints associated with treatment response and the development of the resistant phenotype, which will in turn identify novel transduction pathways worthy of therapeutic development.",
keywords = "Neoadjuvant therapy, Nephrectomy, Renal cell carcinoma, Targeted therapy, Transduction pathways",
author = "Wood, {Christopher G.} and Vitaly Margulis",
year = "2009",
month = "5",
day = "15",
doi = "10.1002/cncr.24240",
language = "English (US)",
volume = "115",
pages = "2355--2360",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "SUPPL. 10",

}

TY - JOUR

T1 - Neoadjuvant (presurgical) therapy for renal cell carcinoma

T2 - A new treatment paradigm for locally advanced and metastatic disease

AU - Wood, Christopher G.

AU - Margulis, Vitaly

PY - 2009/5/15

Y1 - 2009/5/15

N2 - BACKGROUND: Although upfront cytoreductive nephrectomy followed by systemic therapy remains the standard of care for metastatic renal cell carcinoma, the addition of novel targeted therapy has prompted a reevaluation of this treatment paradigm. The authors reviewed their experience with neoadjuvant systemic therapy administered before cytoreductive surgery for metastatic, locally recurrent, or regionally advanced renal cell carcinoma. METHODS: The authors compared patients treated with presurgical targeted therapy (with sunitinib, sorafenib, or bevacizumab) with a contemporary group that underwent upfront cytoreductive surgery. RESULTS: The authors found no difference in any perioperative surgical parameters indicative of morbidity or mortality between the 2 groups. Laboratory models of renal cell carcinoma treated with systemic targeted therapy demonstrate specific protein expression profiles that correlate with response to therapy and the development of therapy resistance. CONCLUSIONS: Neoadjuvant (presurgical) targeted therapy before cytoreductive surgery appears safe in the setting of metastatic renal cell carcinoma. It identifies patients who respond to systemic therapy before surgery, thus avoiding highly morbid surgery in patients destined for a poor outcome. Further studies are needed to identify the molecular endpoints associated with treatment response and the development of the resistant phenotype, which will in turn identify novel transduction pathways worthy of therapeutic development.

AB - BACKGROUND: Although upfront cytoreductive nephrectomy followed by systemic therapy remains the standard of care for metastatic renal cell carcinoma, the addition of novel targeted therapy has prompted a reevaluation of this treatment paradigm. The authors reviewed their experience with neoadjuvant systemic therapy administered before cytoreductive surgery for metastatic, locally recurrent, or regionally advanced renal cell carcinoma. METHODS: The authors compared patients treated with presurgical targeted therapy (with sunitinib, sorafenib, or bevacizumab) with a contemporary group that underwent upfront cytoreductive surgery. RESULTS: The authors found no difference in any perioperative surgical parameters indicative of morbidity or mortality between the 2 groups. Laboratory models of renal cell carcinoma treated with systemic targeted therapy demonstrate specific protein expression profiles that correlate with response to therapy and the development of therapy resistance. CONCLUSIONS: Neoadjuvant (presurgical) targeted therapy before cytoreductive surgery appears safe in the setting of metastatic renal cell carcinoma. It identifies patients who respond to systemic therapy before surgery, thus avoiding highly morbid surgery in patients destined for a poor outcome. Further studies are needed to identify the molecular endpoints associated with treatment response and the development of the resistant phenotype, which will in turn identify novel transduction pathways worthy of therapeutic development.

KW - Neoadjuvant therapy

KW - Nephrectomy

KW - Renal cell carcinoma

KW - Targeted therapy

KW - Transduction pathways

UR - http://www.scopus.com/inward/record.url?scp=65949111709&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=65949111709&partnerID=8YFLogxK

U2 - 10.1002/cncr.24240

DO - 10.1002/cncr.24240

M3 - Article

C2 - 19402066

AN - SCOPUS:65949111709

VL - 115

SP - 2355

EP - 2360

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - SUPPL. 10

ER -